Is oral semaglutide as effective as injection for weight loss?

The biggest misconception: same drug, so same result

A question our prescribers hear regularly goes roughly like this: 'It's semaglutide either way, so why would the tablet be any weaker?' It's a fair assumption, and it's not entirely wrong. The active molecule is identical. The way your body accesses it, though, is not.

When semaglutide is injected under the skin, it passes directly into the bloodstream with consistent, predictable absorption, close to 100% bioavailability. The tablet relies on a different mechanism entirely. It uses an absorption enhancer called SNAC to survive the stomach environment and cross the gut wall, but this process is sensitive to conditions: food in the stomach, coffee, other medicines taken too soon. Bioavailability is in the low single digits as a percentage. The 25mg dose compensates for that, but only if the taking conditions are right.

This is why the NHS semaglutide medicines page and the prescribing information both give the tablet's morning routine such precise instructions. It isn't bureaucratic fussiness. Get it right consistently and the data look quite strong. Let the routine slip and the effective dose the body receives falls.

So the comparison isn't simply 'injection vs. tablet'; it's 'reliable systemic delivery vs. technique-dependent oral delivery'. Both can work well. The correct mental model is that the tablet requires a slightly different kind of discipline than remembering a weekly injection day.

What the trial numbers actually tell you about effectiveness

The OASIS 4 trial enrolled 307 adults with obesity or overweight plus at least one weight-related condition, without type 2 diabetes, over 64 weeks. Average weight loss on the 25mg tablet was around 13.6% versus roughly 2.4% on placebo. Among participants who stayed fully adherent to the treatment protocol, that figure climbed to approximately 17%.

Compare that with the STEP 1 trial of the 2.4mg weekly injection, which found around 15% average weight loss over 68 weeks in a similar population. If you want to understand whether the semaglutide tablet is as effective as the injection, the adherent-participant figure for the tablet sits close to the injection's overall average, which is a useful starting point. Taken at face value, the injection edges ahead on the headline average.

One further complication: the 7.2mg injectable pen, approved by the MHRA on 14 April 2026, reported around 20.7% average weight loss over 72 weeks, territory that had previously been the preserve of tirzepatide. You can read more about how tablets and injections compare across the full semaglutide range if the higher-dose picture is relevant to you.

Numbers from separate trials, run in different populations over different timeframes, are always an indirect comparison. A direct look at the STEP 1 data published in the New England Journal of Medicine is useful context, bearing in mind it predates both the 7.2mg pen and the oral approval. What the trials collectively confirm is that both routes produce meaningful, clinically significant weight loss in people for whom semaglutide is appropriate.

Practical factors that can tip the decision, beyond the percentages

Effectiveness in the abstract is only part of what makes a treatment right for a specific person. A few practical points are worth weighing carefully.

The tablet's morning-routine requirement is real. Swallow it whole with a small glass of plain water (no more than 120ml) then wait at least 30 minutes before coffee, breakfast or any other oral medicine. Check the clock when you take it; one simple habit that takes under a minute is setting a phone timer the moment you swallow. That gap matters because food and liquid interfere with the SNAC absorption mechanism. People who find morning routines naturally structured tend to find this manageable; those with unpredictable schedules sometimes don't.

Storage is a meaningful difference in the other direction. If you are weighing up whether semaglutide oral or injection is the right format for you, it is worth knowing that the tablet requires no refrigeration, which the injection does. For frequent travellers, or anyone without a reliable fridge at home or work, the tablet removes a logistical problem entirely.

Side-effect profiles are broadly similar between routes, nausea, constipation, and other gastrointestinal effects are the most commonly reported with both. The OASIS 4 trial recorded GI side effects in around 74% of tablet participants versus 42% on placebo, generally described as mild to moderate and settling over time. Anyone considering either form should read the patient information leaflet and discuss their medical history with a prescriber. Our guidance on whether semaglutide tablets are as effective as injections covers the evidence in more detail, and you can see a broader overview of what to expect from the Wegovy tablet, including cost context, or explore the full Wegovy tablet overview for more on how the treatment works in practice.

The question of which form suits you is genuinely a clinical one. Our prescribers at nume review each consultation individually, no automated decisions. If you're unsure whether the tablet or injection is the better fit for your circumstances, that conversation is exactly what the consultation is for. Start your free consultation and a GPhC-registered prescriber will assess your situation the same day.